NICE aims to cut funding for Amgen lung cancer drug Lumykras
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
Newsletters and Deep Dive digital magazine
Amgen's Lumykras will no longer be funded by the Cancer Drugs Fund for KRAS-mutated lung cancer, says NHS reimbursement authority NICE.
Boehringer Ingelheim has won the first European approval for its new idiopathic pulmonary fibrosis (IPF) therapy, Jascayd, in the UK.
Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgAN that will compete with Otsuka's recently-launched Voyxact.
Women with endometriosis in England could be offered simple non-invasive tests for diagnosis of their condition, rather than a surgical procedure.
A series of pilot schemes set up by the UK in partnership with the pharma industry will test ways to get new medicines to patients more quickly.
Editor's Picks
Newsletters and Deep Dive
digital magazine